Clindamycin Phosphate

- Overview
  - Clindamycin Phosphate (Clindamycin-2-phosphate) is a broad-spectrum antibiotic and antiparasitic agent. It is a semi-synthetic derivative of Lincomycin, a natural lincosamide from Streptomyces lincolnensis. Clindamycin Phosphate is freely soluble in water.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Lincosamides inhibit bacterial protein synthesis by binding the 50S ribosomal subunit and interfering with tRNA activity during translation.
- Properties
  - CAS Number
    
    24729-96-2
    
    Molecular Formula
    
    C18H34ClN2O8PS
    
    Molecular Weight
    
    504.96
    
    Appearance
    
    White or almost white crystalline powder
    
    Solubility
    
    freely soluble in aqueous solution.
    
    Other Properties
    
    Source: Semi-synthetic
    Water Content (Karl Fischer): ≤6.0%
    PH: 3.5-4.5
    Assay: ≥758 µg/mg
    
    Storage
    
    Store at room temperature in an airtight container
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Clindamycin is a broad-spectrum antibiotic targeting primarily Gram-positive and Gram-negative bacteria such as Clostridium and Bacteroides species. It is also effective against protozoa.
    
    Microbiology Applications: Clindamycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative anaerobes. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative concentration ranges include: Bacteroides fragilis 0.25 µg/mL - 4 µg/ml Clostridium difficile 0.25 µg/mL - 32 µg/mL .
    
    Eukaryotic Cell Culture Applications: HIV-infected cells (MOLT3 cells) were incubated with increasing concentrations of Clindamycin with no impact on cell death (Wijsman et al, 2013). The effects of Clindamycin and its metabolites on mammalian cell lines (mouse leukemia L1210, human oral carcinoma KB, human acute myelogenous leukemia RPMI 6410, and human lymphocyte RPMI 1788) were evaluated. Metabolites clindamycin sulfoxide and clindamycose were nontoxic, whereas N-demethyl clindamycin showed cytotoxic effects in culture (Li et al, 1977).